Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922050 · ClinicalTrials.gov registry record · Phase 1
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
NCT01922050 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 320 participants.
The verdict
NCT01922050, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
Study Summary
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle formulations
Interventions
- DRUG LEO 43204 Formulation 1
- DRUG LEO 43204 Formulation 2
- DRUG LEO 43204 Formulation 1 Dose X
- DRUG LEO 43204 Formulation 1 Dose Y
- DRUG LEO 43204 Formulation 2 Dose XX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01922050
The ClinicalTrials.gov registry entry for NCT01922050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which LEO 43204 Formulation 1 is the first listed.
NCT01922050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01922050 about?
NCT01922050 is a clinical study titled "A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis". Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle formulati...
What is the current status of trial NCT01922050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2013-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01922050?
The interventions under investigation include: LEO 43204 Formulation 1 (DRUG), LEO 43204 Formulation 2 (DRUG), LEO 43204 Formulation 1 Dose X (DRUG), LEO 43204 Formulation 1 Dose Y (DRUG), LEO 43204 Formulation 2 Dose XX (DRUG).
Who is sponsoring clinical trial NCT01922050?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.